STUDY PARTICIPANTS
Who could take part in the study?
To be able to take part in the study, each patient had to meet the following requirements:
Male or female, 18 years Abnormal LDH levels, No previous treatment with
of age or older platelet count, and eculizumab or ravulizumab
creatinine levels
Complement inhibitors increase the risk of potentially life-threatening meningococcal infection,
which is caused by a germ called Neisseria meningitidis. To help prevent meningococcal disease, all
patients had to be adequately vaccinated before receiving ravulizumab.
Where was the study done?
The study is being done in 41 study centers in 14 countries across North America, Asia, Europe,
and Australia. It started in March 2017 and is still ongoing.
How many patients took part in the study?
+ =
19 39 58
men women patients
Patients were between 19 and 77 years of age and from diverse ethnic backgrounds.
Protocol, ALXN1210-aHUS-311 SPONSOR CONTACT INFORMATION:
Europe, 2016-002027-29 1-888-765-4747
Â© Certara USA, Inc. 2020. All rights reserved United States, NCT02949128 medinfo@alexion.com 5